Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adia MedADIA 14 14-Day RSI is 53.40 as of Aug. 01, 2026. GuruFocus rates ADIA with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 698 Healthcare Providers & Services companies, Adia Med ranks worse than 65.76% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-01), Adia Med's 14-Day RSI is 53.40.
The industry rank for Adia Med's 14-Day RSI or its related term are showing as below:
ADIA's 14-Day RSI is ranked worse than 65.76% of 698
companies
in the Healthcare Providers & Services industry
Industry Median: 48.765
vs ADIA: 53.40
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Adia Med 14-Day RSI Related Terms
ADIA vs GBCS, CCM, CDIX: 14-Day RSI Comparison
For the Medical Care Facilities subindustry, Adia Med's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adia Med 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Adia Med's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Adia Med's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adia Med (ADIA) has a 14-Day RSI of 53.40 as of Aug. 01, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Adia Med and its competitors. According to the industry distribution chart, Adia Med ranks #459 out of 698 companies in the Healthcare Providers & Services industry, placing it in the top 65.8%.
Is Adia Med's 14-Day RSI too high?
Adia Med's current 14-Day RSI is 53.40. The Healthcare Providers & Services industry median 14-Day RSI is 48.77. Adia Med's value of 53.40 is 9.5% above this industry median. Based on the distribution chart, Adia Med ranks #459 out of 698 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Adia Med has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Adia Med's 14-Day RSI compare to GBCS and CCM?
According to the Healthcare Providers & Services industry distribution chart, Adia Med ranks #459 out of 698 companies for 14-Day RSI. This places Adia Med in the lower half of its industry. The industry median 14-Day RSI is 48.77. Adia Med's value of 53.40 is 9.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 48.77, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adia Med's current 14-Day RSI of 53.40 is 9.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Adia Med and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 48.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adia Med's current 14-Day RSI is 53.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adia Med stock overvalued right now?
Adia Med (ADIA) has a current 14-Day RSI of 53.40. The current 14-Day RSI is 53.40 and 9.5% above the Healthcare Providers & Services industry median of 48.77. Adia Med's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Adia Med (ADIA), the current 14-Day RSI is 53.40 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adia Nutrition Inc focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Its products and the deployment of the therapies utilizing its products address various orthopedic issues, pain management, and wound repair. In addition, its products are able to be utilized in various other therapies to address anti-aging issues and other tissue repair desires. It operates in three segments The Biolete segment comprises the sale of supplements; Adia Med performs stem cell treatments to patients; and Adia Labs procures and sells stem cell products to outside clinics or to Adia Med. It derives revenue from Sales of supplements, Medical procedures, Sales of biologics and ancillary products.
14GF Score
Get the complete analysis for ADIA
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADIA has been successfully added to your 
